Insomnia is a common problem for children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Research has shown that daytime drowsiness because of insufficient sleep can lead to learning and attention problems.
A new clinical trial, posted November 2005 on the www.clinicaltrials. gov Web site, is recruiting children and adolescents with ADHD-related insomnia. The purpose of the study is to examine the effects of a nonstimulating drug, atomoxetinewhich is indicated for the treatment of ADHDon ADHD-related insomnia. A majority of drugs indicated for the treatment of ADHD symptoms in children and adults are stimulating and can aggravate sleep problems. There is evidence that the trial's drug may improve sleep in children with ADHD.
Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.
Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?
Clinical features with downloadable PDFs